Regular review after lung cancer surgery is mainly to check whether there will be metastasis and recurrence. Review cannot stop the metastasis of tumor, but can detect cancer early and take treatment measures as soon as possible. This article introduces the review time of lung cancer and tumor markers of lung cancer.
Time of lung cancer review Time and content of lung cancer review.
3 months chest CT, abdominal ultrasound (liver, gallbladder, pancreas, spleen, adrenal gland)
6 months chest CT, abdominal ultrasound (liver, gallbladder, pancreas, spleen, adrenal gland), head CT, bone scan (ECT), tumor markers
9 months CT chest, ultrasound abdomen (liver, gallbladder, pancreas, spleen, adrenal gland)
12 months CT chest, ultrasound abdomen (liver, gallbladder, pancreas, spleen, adrenal gland), CT head, bone scan (ECT), tumor markers
18 months CT chest, ultrasound abdomen (liver, gallbladder, pancreas, spleen, adrenal gland), CT head, bone scan (ECT), tumor markers
24 months CT chest, ultrasound abdomen (liver, gallbladder, pancreas, spleen, adrenal gland), CT head, bone scan (ECT), tumor markers
30 months CT chest, ultrasound abdomen (liver, gallbladder, pancreas, spleen, adrenal gland), CT skull, bone scan (ECT), tumor markers
36 months CT chest, ultrasound abdomen (liver, gallbladder, pancreas, spleen, adrenal gland), CT skull, bone scan (ECT), tumor markers
42 months CT chest, ultrasound abdomen (liver, gallbladder, pancreas, spleen, adrenal gland), CT skull, bone scan (ECT), tumor markers
48 months CT chest, ultrasound abdomen (liver, gallbladder, pancreas, spleen, adrenal gland), CT skull, bone scan (ECT), tumor markers
54 months CT chest, ultrasound abdomen (liver, gallbladder, pancreas, spleen, adrenal gland), CT skull, bone scan (ECT), tumor markers
60 months chest CT, abdominal ultrasound (liver, gallbladder, pancreas, spleen, adrenal gland), cranial CT, bone scan (ECT), tumor markers
What are the tumor markers for lung cancer?
Neurospecific enolase (NSE): NSE is quite specific and has abnormal overexpression in small cell lung cancer, so it is the preferred marker for small cell lung cancer, with a positive rate of 65% to 81%, while in non-small cell lung cancer, serum NSE is elevated in less than 20%, so it can be used as an indicator to distinguish small cell lung cancer from non-small cell lung cancer. In addition, NSE is significantly higher in patients with progressive lung cancer than in those with non-progressive lung cancer, and the level of NSE decreases when treatment is effective, so NSE can be used both for the diagnosis of small cell lung cancer and for monitoring treatment response.
SCC antigen: SCC is considered to be a highly specific marker for squamous cell carcinoma because it has a 50% positive rate in lung squamous cell carcinoma, compared to less than 30% in other lung cancers. Many squamous cell carcinoma recurrence can be seen as a “rebound” of serum SCC level, so SCC can be used as a recurrence monitor for squamous cell carcinoma. Non-malignant lung tumors can have 10%-15% false positives.
Carcinoembryonic antigen (CEA): CEA can only be measured in trace amounts in normal human serum, and it has been confirmed that lung cancer cells can directly produce CEA, so the measurement of CEA in serum can be used as an indicator for the diagnosis of lung cancer. The value of CEA in the early diagnosis of lung cancer needs to be further investigated.
Superoxide dismutase (SOD): Due to the damage of oxygen free radicals to cell membrane and tumor cell necrosis, Mn-SOD in cancer cells spills into extracellular fluid and is detected. the sensitivity of Mn-SOD for lung cancer diagnosis is 86.11%, specificity 91.18%, correct diagnosis rate 88.57%, and it has a high detection rate for all types of lung cancer, Mn-SOD in stage III and IV patients is higher than that in stage I and II patients. The Mn-SOD of stage III and IV patients is higher than that of stage I and II, so the Mn-SOD measurement has practical value for the diagnosis and efficacy determination of lung cancer.
Gastrin: The specificity and accuracy of serum gastrin-releasing peptide precursor (pro-GRP) in small cell lung cancer was 9r7. 7%, which was significantly higher than the level in non-small cell lung cancer, benign lung disease and healthy individuals, so it is believed that pro-GRP can be used as an indicator to distinguish small cell lung cancer from non-small cell lung cancer.
Serum ferritin (sF): The positive rate of elevated sF in lung cancer patients ranges from 30% to 80%, with an accuracy of 76%, sensitivity of 73%, and specificity of 80% for the diagnosis of lung cancer. Normal lung tissue has no ferritin receptor expression. Therefore, the detection of sF is of clinical value for the diagnosis of lung cancer, assessment of efficacy, and monitoring of recurrence and metastasis, but it needs to be differentiated from patients with elevated serum sF levels such as pulmonary heart disease, lung sensory beams, and pleurisy.
CYFPA21-1: It has been used for clinical testing since 1992 and is a useful marker and first marker for non-small cell lung cancer, with a specificity of 95% and sensitivity of 49%, especially for the diagnosis of squamous carcinoma with a higher sensitivity of 60%.
CAl5-3: Although it is found in breast cancer, it can have a 50% positive rate in lung adenocarcinoma and large cell carcinoma. CAl25 can have a 50% positive rate in various lung cancers.
The detection of one tumor marker alone often has low specificity and less than ideal sensitivity, so clinically multiple 1 tumor markers are often used in combination to improve the level of diagnosis and increase the positive rate of diagnosis.